Tag: Occupational Hazards

Effect of intubation barrier devices on aerosol exposure

Editor's Note Barrier devices used for intubation may reduce operator exposure to infectious droplets and aerosols, but there is wide variation in aerosol containment, this study finds. Fully enclosed barrier devices reduced vapor and aerosol content in the area of the operator. If no barrier device was used, aerosol content…

Read More

By: Judy Mathias
December 14, 2020
Share

Safety, efficacy of BNT162b2 mRNA (Pfizer/BioNTech) COVID-19 vaccine

Editor's Note This study reports the safety and efficacy findings of the phase 2 and phase 3 parts of the clinical trial of the BNT162b2 mRNA (Pfizere/BioNTech) vaccine in preventing COVID-19 in persons 16 years of age or older. These results are the basis for an application for emergency use…

Read More

By: Judy Mathias
December 10, 2020
Share

US could begin distributing 2.9 M COVID-19 vaccine doses this week

Editor's Note Gen Gustave Perna, who oversees logistics for Operation Warp Speed, announced December 8 that the government is prepared to distribute 2.9 million doses of Pfizer/BioNTech’s COVID-19 vaccine by the end of this week or immediately after the vaccine receives emergency use authorization (EUA) from the Food and Drug…

Read More

By: Judy Mathias
December 10, 2020
Share

Healthcare workers’ COVID-19 infections largely associated with community, home exposure

Editor's Note This study by researchers at Northwestern University, Feinberg School of Medicine, Chicago, finds that out-of-hospital (community and home) exposure to COVID-19 had the largest association with seropositive status of healthcare workers. Of 6,150 healthcare workers analyzed, nurses, medical assistants, and support services workers were at highest risk for…

Read More

By: Judy Mathias
December 10, 2020
Share

FDA confirms efficacy of Pfizer COVID-19 vaccine, on cusp of EUA

Editor's Note The Food and Drug Administration (FDA), on December 8, released documents that confirmed the safety and efficacy of Pfizer’s COVID-19 vaccine, the Associated Press reports. The vaccine was co-developed with BioNTech. FDA regulators posted their analysis online, as the UK began administering doses of the vaccine to its…

Read More

By: Judy Mathias
December 8, 2020
Share

Large US study confirms COVID-19 complications

Editor's Note This large US study of patients who contracted COVID-19 confirms and provides risk estimates for numerous complications of the disease. Using US health claims data of 70,288 patients who had a COVID-19-related healthcare visit between March 1 and April 30, 2020, researchers found that 53.4% were admitted to…

Read More

By: Judy Mathias
December 8, 2020
Share

CDC: Implementing COVID-19 mitigation strategies in child care settings

Editor's Note This study led by researchers at the Centers for Disease Control and Prevention (CDC) finds that implementing and monitoring adherence to recommended COVID-19 mitigation strategies can reduce the risk for transmission in child care settings. In collaboration with the Department of Health and Human Services’ Administration for Children…

Read More

By: Judy Mathias
December 8, 2020
Share

Huddles may be the best way for healthcare workers to communicate during COVID-19

Editor's Note Brief huddles, rather than a barrage of emails and texts about safety and risk may be the fastest and simplest way for healthcare workers to avoid communication overload from COVID-19, this study from Baylor University reports. Interviews of 40 workers in two hospitals found the following: Healthcare workers…

Read More

By: Judy Mathias
December 7, 2020
Share

CDC shortens quarantine days for COVID-19

Editor's Note The Centers for Disease Control and Prevention (CDC) on December 2 changed its recommended quarantine period for people who have come in contact with COVID-19 positive individuals. Instead of the standard 14 days, the CDC now allows individuals who have come in contact with someone infected with the…

Read More

By: Judy Mathias
December 3, 2020
Share

Durablity of response to COVID-19 mRNA-1273 vaccination

Editor's Note This study led by the National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, finds that vaccinations with mRNA-1273 (Moderna) have the potential to provide durable humoral immunity. This report describes immunogenicity data for mRNA-1273 at 119 days after the first vaccination and 90 days after the second…

Read More

By: Judy Mathias
December 3, 2020
Share

Join our community

Learn More
Video Spotlight
Live chat by BoldChat